Intel stock extends gains after report of possible U.S. government stake
Director Rebecca Taub of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) sold 41,343 shares of common stock on August 11 and 12, 2025, for approximately $16.5 million. The sales were executed at prices ranging from $350.1773 to $359.7108. The stock, currently trading at $373.46, has shown remarkable strength with a 10.46% gain in the past week. According to InvestingPro analysis, the company’s shares are currently trading slightly below their Fair Value.
Taub also exercised options to acquire 46,463 shares of Madrigal Pharmaceuticals common stock at a price of $9.45 per share, for a total value of $439075.
The sales were executed under a Rule 10b5-1 trading plan adopted on March 14, 2025.
Following these transactions, Taub directly owns 461,044 shares of Madrigal Pharmaceuticals, Inc. In addition, Taub indirectly owns 655,540 shares through SQN LLC. Want deeper insights into Madrigal’s valuation and insider trading patterns? Access the full Pro Research Report, available exclusively on InvestingPro.
In other recent news, Madrigal Pharmaceuticals reported robust second-quarter earnings, with Rezdiffra sales reaching $212.8 million, significantly surpassing Goldman Sachs’ estimates of $150.9 million and FactSet’s consensus of $159.4 million. The company attributed this strong performance to increased patient demand and greater prescriber penetration. Additionally, Madrigal has entered into an exclusive global license agreement with CSPC Pharmaceutical Group for SYH2086, a preclinical oral GLP-1 receptor agonist, involving an upfront payment of $120 million and potential milestone payments up to $2 billion. The agreement is pending regulatory clearance and is expected to close in the fourth quarter of 2025. Madrigal also secured a $500 million credit facility with Blue Owl Capital, including a $350 million initial term loan, to advance its MASH pipeline. Piper Sandler reiterated an Overweight rating on Madrigal, expressing confidence in the progress of Rezdiffra’s launch. Jefferies raised its price target on Madrigal stock to $502 from $411, following a patent extension for Rezdiffra that extends protection until February 2045. Goldman Sachs reiterated its buy recommendation, citing the strong sales performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.